EUVIMEDEUVIMED entdecken
FallberichtÜbersichtsarbeit

ETV6-NTRK2 Fusion in a Patient With Metastatic Pulmonary Atypical Carcinoid Successfully Treated With Entrectinib: A Case Report and Review of the Literature

Wusheng Zhang, Sen Tian, Xiang Li, Yilin Chen, Xinyu Wang, Yunshuo Zhang, Lihui Lv, Yonghua Li, Hui Shi, Chong Bai

Clinical Lung Cancer · 2024-05 · 25 (3) · 215-224.e3

DOI: 10.1016/j.cllc.2024.03.005 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Clinical Lung Cancer, 2024-05. Verfasst von Wusheng Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Naval Medical University, Shanghai, China. Hauptthemen laut MEDLINE: Carcinoid Tumor, Lung Neoplasms, Oncogene Proteins, Fusion, Indazoles. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 90 Literaturangaben. Gefördert von: Shanghai Municipal Health Commission, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pulmonary atypical carcinoid (AC) is an extremely rare neuroendocrine tumor. The neurotrophic tropomyosin receptor kinase (NTRK) fusions are reported in only 0.5% of nonsmall cell lung cancer, and are more rare in AC with only one previously reported case. Currently, there is little established evidence on the optimal therapeutic strategies and prognosis for advanced cases. We present a female patient with metastatic AC after complete resection. Due to low expression of somatostatin receptor in this case, somatostatin analogs and peptide receptor radionuclide therapy were not available. After pursuing other alternative treatments, including chemotherapy (ie, carboplatin, etoposide, capecitabine, temozolomide, and paclitaxel), everolimus, and atezolizumab, she returned with significant progression, including innumerable subcutaneous nodules, left pleura metastasis, multiple bone metastases, and brain metastases. New biopsy analysis revealed an ETV6-NTRK2 fusion. She was immediately administered the first-generation tropomyosin receptor kinase inhibitor entrectinib at a dose of 600 mg q.d. A subsequent month of treatment resulted in a complete response in all of the metastatic lung lesions. To date, she has maintained sustained benefit for at least 1 year from initiation of entrectinib. Here, we present the first case of a female patient with metastatic AC harboring the ETV6-NTRK2 fusion, and successfully treated with entrectinib, providing evidence for the application of entrectinib in patients with NTRK-positive AC, and underscoring the critical role of molecular profiling for such cases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoid TumorLung NeoplasmsOncogene Proteins, FusionIndazolesBenzamidesHumansFemaleMiddle AgedReceptor, trkBProtein Kinase InhibitorsMembrane Glycoproteins

Stichwörter der Autor:innen

Neurotrophic tropomyosin receptor kinase (NTRK)Next-generation sequencing (NGS)Non-small cell lung cancer (NSCLC)Pulmonary carcinoids (PCs)Treatment

Substanzen

Oncogene Proteins, FusionIndazolesBenzamidesReceptor, trkBProtein Kinase InhibitorsMembrane Glycoproteinsentrectinibtropomyosin-related kinase-B, human

Autor:innen und Institutionen

  • Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Naval Medical University, Shanghai, China.
  • Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Naval Medical University, Shanghai, China; Department of Respiratory and Critical Care Medicine, No. 906 Hospital of the Chinese Peo…
  • Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Naval Medical University, Shanghai, China; Department of Respiratory and Critical Care Medicine, General Hospital of Central Theater…
  • Department of Pathology, The First Affiliated Hospital of Naval Medical University, Shanghai, China.
  • Department of Respiratory and Critical Care Medicine, No. 906 Hospital of the Chinese People's Liberation Army Joint Logistic Support Force, Ningbo, China.
  • Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Naval Medical University, Shanghai, China. Electronic address: Huishi@smmu.edu.cn.

Förderung

  • Shanghai Municipal Health Commission
  • National Natural Science Foundation of China

Zitieren

APA

Zhang, W., Tian, S., Li, X., Chen, Y., Wang, X., Zhang, Y., Lv, L., Li, Y., Shi, H., & Bai, C. (2024). ETV6-NTRK2 Fusion in a Patient With Metastatic Pulmonary Atypical Carcinoid Successfully Treated With Entrectinib: A Case Report and Review of the Literature. Clinical Lung Cancer, 25(3), 215-224.e3. https://doi.org/10.1016/j.cllc.2024.03.005

Vancouver

Zhang W, Tian S, Li X, Chen Y, Wang X, Zhang Y, et al. ETV6-NTRK2 Fusion in a Patient With Metastatic Pulmonary Atypical Carcinoid Successfully Treated With Entrectinib: A Case Report and Review of the Literature. Clinical Lung Cancer. 2024;25(3):215-224.e3. doi:10.1016/j.cllc.2024.03.005

BibTeX
@article{Zhang2024,
  author = {Zhang, Wusheng and Tian, Sen and Li, Xiang and Chen, Yilin and Wang, Xinyu and Zhang, Yunshuo and Lv, Lihui and Li, Yonghua and Shi, Hui and Bai, Chong},
  title = {ETV6-NTRK2 Fusion in a Patient With Metastatic Pulmonary Atypical Carcinoid Successfully Treated With Entrectinib: A Case Report and Review of the Literature},
  journal = {Clinical Lung Cancer},
  year = {2024},
  volume = {25},
  number = {3},
  pages = {215--224.e3},
  doi = {10.1016/j.cllc.2024.03.005}
}
Kostenlos starten →